tetano
Editor, Senior Moderator
ACS Omega
. 2021 Jun 11;6(24):15988-15999.
doi: 10.1021/acsomega.1c01785. eCollection 2021 Jun 22.
Impact of Expressing Cells on Glycosylation and Glycan of the SARS-CoV-2 Spike Glycoprotein
Yan Wang[SUP] 1 [/SUP], Zhen Wu[SUP] 2 [/SUP], Wenhua Hu[SUP] 3 [/SUP], Piliang Hao[SUP] 4 [/SUP], Shuang Yang[SUP] 3 [/SUP]
Affiliations
Abstract
The spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the first point of contact for the virus to recognize and bind to host receptors, is the focus of biomedical research seeking to effectively prevent and treat coronavirus disease (COVID-19). The mass production of spike glycoproteins is usually carried out in different cell systems. Studies have been shown that different expression cell systems alter protein glycosylation of hemagglutinin and neuraminidase in the influenza virus. However, it is not clear whether the cellular system affects the spike protein glycosylation. In this work, we investigated the effect of an expression system on the glycosylation of the spike glycoprotein and its receptor-binding domain. We found that there are significant differences in the glycosylation and glycans attached at each glycosite of the spike glycoprotein obtained from different expression cells. Since glycosylation at the binding site and adjacent amino acids affects the interaction between the spike glycoprotein and the host cell receptor, we recognize that caution should be taken when selecting an expression system to develop inhibitors, antibodies, and vaccines.
. 2021 Jun 11;6(24):15988-15999.
doi: 10.1021/acsomega.1c01785. eCollection 2021 Jun 22.
Impact of Expressing Cells on Glycosylation and Glycan of the SARS-CoV-2 Spike Glycoprotein
Yan Wang[SUP] 1 [/SUP], Zhen Wu[SUP] 2 [/SUP], Wenhua Hu[SUP] 3 [/SUP], Piliang Hao[SUP] 4 [/SUP], Shuang Yang[SUP] 3 [/SUP]
Affiliations
- PMID: 34179644
- PMCID: PMC8204757
- DOI: 10.1021/acsomega.1c01785
Abstract
The spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the first point of contact for the virus to recognize and bind to host receptors, is the focus of biomedical research seeking to effectively prevent and treat coronavirus disease (COVID-19). The mass production of spike glycoproteins is usually carried out in different cell systems. Studies have been shown that different expression cell systems alter protein glycosylation of hemagglutinin and neuraminidase in the influenza virus. However, it is not clear whether the cellular system affects the spike protein glycosylation. In this work, we investigated the effect of an expression system on the glycosylation of the spike glycoprotein and its receptor-binding domain. We found that there are significant differences in the glycosylation and glycans attached at each glycosite of the spike glycoprotein obtained from different expression cells. Since glycosylation at the binding site and adjacent amino acids affects the interaction between the spike glycoprotein and the host cell receptor, we recognize that caution should be taken when selecting an expression system to develop inhibitors, antibodies, and vaccines.